Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

E. Ben-Ami, C. M. Barysauskas, M. von Mehren, M. C. Heinrich, C. L. Corless, J. E. Butrynski, J. A. Morgan, A. J. Wagner, E. Choy, J. T. Yap, A. D. Van den Abbeele, S. M. Solomon, J. A. Fletcher, G. D. Demetri, Suzanne George

Research output: Contribution to journalArticlepeer-review

53 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences